Search

In an article featured in BioSpectrum India, Atif Khan, a scientist at the Biofouling and Biofilm Processes Section of the Bhabha Atomic Research Centre, India discusses the likely establishment of phage infrastructure in India within the n

The phage therapy biotech company Ampliphi Biosciences is merging with C3J Therapeutics, a synthetic phage/antimicrobial engineering company.

Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.

Our opinion piece, A Bright Outlook for Bacteriophage Applications, is featured in the Microbiome Times January 2019 edition (page 34).

How big is the market for bacteriophage products? One group estimates that number to be $567.9 million USD.

Our opinion piece, A Bright Outlook for Bacteriophage Applications, is featured in the Microbiome Times January 2019 edition (page 34).

Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.

The phage therapy biotech company Ampliphi Biosciences is merging with C3J Therapeutics, a synthetic phage/antimicrobial engineering company.

How big is the market for bacteriophage products? One group estimates that number to be $567.9 million USD.